Review paper
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Abstract
Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2 gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin receptor imaging (SRI). Patients with metastatic high-grade (WHO G3) gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC) represent a heterogeneous subgroup with poor prognosis and standard platinum-etoposide chemotherapy have limited therapeutic benefit....
Paper Details
Title
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Published Date
Mar 1, 2020
Journal
Volume
27
Issue
3
Pages
R67 - R77
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History